Key result
Oritavancin consolidation therapy linked to ~84% clinical cure in infective endocarditis.
Why the study?
Infective endocarditis requires prolonged antimicrobial therapy, and the long-acting lipoglycopeptide oritavancin has emerged as a potential off-label treatment option whose effectiveness, safety, and treatment strategies in adults warranted systematic evaluation.
What are the clinical effectiveness, safety, and dosing strategies of oritavancin in adult patients with infective endocarditis?
Systematic Review (n=54)
Yes
What are the clinical effectiveness, safety, and dosing strategies of oritavancin in adult patients with infective endocarditis?
Oritavancin shows an 83.7% clinical cure rate when used primarily as sequential or consolidation therapy in selected patients with Gram-positive infective endocarditis, though prospective trials are needed to establish standardized dosing and independent efficacy.
Answers are grounded in this paper and cite their sources.
Supports sequential oritavancin in selected Gram-positive IE; leaves open prospective trials to confirm dosing and independent efficacy.
BACKGROUND: Infective endocarditis (IE) requires prolonged antimicrobial therapy. Oritavancin, a long-acting lipoglycopeptide active against Gram-positive pathogens, has emerged as a potential off-label treatment option. OBJECTIVES: To evaluate the effectiveness, safety and treatment strategies of oritavancin in adults with IE. METHODS: A systematic review was conducted according to PRISMA 2020. Electronic database and registry searches were supplemented by forward and backward citation searching. Data on IE subtype, pathogens, dosing, treatment duration, surgery, adverse events and clinical outcomes were synthesized descriptively. RESULTS: Fifteen studies comprising 54 patients were included. Among 49 patients with evaluable outcomes, 41 (83.7%) achieved clinical cure. Native valve endocarditis was the most common subtype (22/47, 46.8%), followed by prosthetic valve endocarditis (18/47, 38.3%) and cardiac device-related IE (5/47, 10.6%). Staphylococcus aureus (17/50, 34.0%) and Enterococcus faecalis (14/50, 28.0%) were the most frequently reported pathogens. A single 1200 mg dose was the most common dosing scheme (14/48, 29.1%), although multiple-dose regimens were used. Median total dose was 2400 mg (IQR 1200-4800), and median calendar-based treatment duration was 9 days (IQR 1-28). Six patients experienced adverse events among 40 with available safety data. CONCLUSIONS: Oritavancin was associated with clinical cure in most evaluable reported cases and was used predominantly as sequential or consolidation therapy. Evidence remains limited to small observational studies and case reports with heterogeneous treatment strategies and incomplete follow-up. Prospective studies are needed to define optimal dosing and clarify the role of oritavancin in IE management.
No takes yet. Share an insight, caveat, or question.
Giouglis et al. (2026) conducted a systematic review in Infective endocarditis (IE) (n=54). Oritavancin was evaluated on Clinical cure (clinical resolution or substantial improvement of signs and symptoms of IE without persistent/recurrent infection or deterioration). Oritavancin, used predominantly as sequential or consolidation therapy, was associated with an 83.7% (41/49) clinical cure rate in adults with infective endocarditis.
Synapse has enriched 10 related papers. Consider them for comparative context: